Selection from HEOR Bibliography
| Search criteria | ||||
| Denmark |
||||
| Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | ||||
| Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group | ||||
| "1 Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel 2 Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany 3 German Centre for Diabetes Research (DZD), München-Neuherberg, Germany 4 Department of Health Service Administration, China Medical University, Taichung, Taiwan 5 Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan 6 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 7 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 8 Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan 9 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 10 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 11 Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK 12 Institute of Applied Health Research, University of Birmingham, Birmingham, UK 13 Midlands Health Data Research UK, Birmingham, UK 14 DEMAND Hub, University of Birmingham, Birmingham, UK 15 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden 16 Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland 17 IQVIA Solutions Denmark A/S, Copenhagen, Denmark 18 IQVIA, Espoo, Finland 19 IQVIA, Tartu, Estonia 20 Boehringer Ingelheim International GmbH, Ingelheim, Germany 21 Boehringer Ingelheim International GmbH, US 22 Lilly Deutschland GmbH, Bad Homburg, Germany 23 Steno Diabetes Center Copenhagen, Herlev, Denmark 24 Department of Public Health, University of Copenhagen, Copenhagen, Denmark 25 Department of Cardiology, Oslo University Hospital UllevÃ¥l, and University of Oslo, Oslo, Norway 26 Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway 27 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA 28 Department of Cardiology, Hospital ClÃnico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" | ||||
| "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636 Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October" |
||||
| , Article | ||||
| , Denmark, Finland, Germany, Norway, Spain, Sweden, UK | ||||
| Abstract: https://doi.org/10.1016/j.diabet.2022.101418 (https://www.sciencedirect.com/science/article/pii/S1262363622000994) | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study | 2023 | English | , Clinical setting: hospital, Clinical setting: Primary care | |
| The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis | ||||
| Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore, Aida Aydemir, Irene Bezemer & Meritxell Sabidó | ||||
| "a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia; b The Alfred Hospital, Melbourne, VIC, Australia; c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland; e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany; f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland; g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland; h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; i Department of Clinical Medicine, University of Bergen, Bergen, Norway; j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; l Bordeaux PharmacoEpi (BPE), Universit�e de Bordeaux, Bordeaux, France; m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA; n Global Epidemiology, IQVIA, Amsterdam, The Netherlands; o Merck Healthcare KGaA, Darmstadt, Germany" | ||||
| , Article | ||||
| , Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey | ||||
| Abstract: https://www.tandfonline.com/doi/full/10.1080/03007995.2023.2256220 | ||||
| Condition | Year | Language | Analysis type | |
| , Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders | 2023 | English | , clinical setting: Secondary care, Epidemiological study, Population Based Study | |
| The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets | ||||
| Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group | ||||
| 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia. 2The Alfred Hospital, Melbourne, Australia. 3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France. 4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA). 5Global Database Studies, IQVIA, Tartu, Estonia. 6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands. 7IQVIA (former EPID Research), Espoo, Finland. 8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany. | ||||
| Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977 |
||||
| , Article | ||||
| , Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/35357268/ | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Neurological disorders | 2022 | English | , clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis | |
| Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018 | ||||
| Janet Sultana 1 2, Salvatore Crisafulli 3, Mariana Almas 4, Ippazio Cosimo Antonazzo 5 6, Esme Baan 7, Claudia Bartolini 6, Maria Paola Bertuccio 3, Fedele Bonifazi 8 9, Annalisa Capuano 10 11, Antonella Didio 8 9, Vera Ehrenstein 12, Mariagrazia Felisi 8 13, Carmen Ferrajolo 10 11, Andrea Fontana 14, Remy Francisca 7, Annie Fourrier-Reglat 15, Joan Fortuny 16, Rosa Gini 6, Giulia Hyeraci 6, Christel Hoeve 7, Christos Kontogiorgis 17, Valentina Isgrò 18, Panagiotis-Nikolaos Lalagkas 17, Luca L'Abbate 18, Deborah Layton 19, Annalisa Landi 8 9, Silvia Narduzzi 19, Leonardo Roque Pereira 20, Georgios Poulentzas 17, Concetta Rafaniello 10 11, Giuseppe Roberto 6, Giulia Scondotto 3, Liberata Sportiello 10 11, Maddalena Toma 8 9, Massoud Toussi 19, Katia Verhamme 7, Elisabetta Volpe 8 9, Gianluca Trifirò 18, | ||||
| Pharmacy Department, Mater Dei Hospital, Msida, Malta. 2Exeter College of Medicine and Health, Exeter, UK. 3Department of Medicine, University of Verona, Verona, Italy. 4Real World Solutions Department, IQVIA, Lisbon, Portugal. 5Research Centre on Public Health (CESP), University of Milan-Bicocca, Milan, Italy. 6Agenzia Regionale di Sanità della Toscana, Florence, Italy. 7Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, The Netherlands. 8TEDDY European Network of Excellence for Paediatric Clinical Research, Pavia, Italy. 9Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus, Bari, Italy. 10Department of Experimental Medicine, University of Campania "Vanvitelli", Naples, Italy. 11Campania Regional Center of Pharmacovigilance and Pharmacoepidemiology, Naples, Italy. 12Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. 13CVBF Consorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy. 14Unit of Biostatistics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. 15Univ. Bordeaux, INSERM, Bordeaux Population Health Research Center, Team of Pharmacoepidemiology, UMR 1219, Bordeaux, France. 16RTI Health Solutions, Barcelona, Spain. 17Democritus University of Thrace, Alexandroupolis, Greece. 18Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 19Data Science Hub, Real World Solutions, IQVIA, London, UK. 20Department of Datascience & Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands. | ||||
| Pharmacoepidemiol Drug Saf . 2022 Jun;31(6):689-705. doi: 10.1002/pds.5413. Epub 2022 Feb 11. |
||||
| , Article | ||||
| , Denmark, France, Italy, Netherlands, Portugal, Spain, UK | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/35092329/ | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Drug Utlization Study | 2022 | English | , Database Study, Review | |
| Validation of safety outcomes in routinely collected data: lessons learned from a multinational post-approval safety study | ||||
| Arena PJ, Huang K, Löfling L, Bahmanyar S, Mo J, Schachterle SE, Nunes AP, Smits E, Juuti R, Hoti F, Korhonen P, Adelborg K, Sundbøll J, Rasmussen TR, Løkke A, Ehrenstein V. | ||||
| "Pfizer Inc., New York, New York, United States of America. Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California, United States of America. EPID Research (an IQVIA company), Espoo, Finland." | ||||
| Pharmacoepidemiol Drug Saf. 2022 Dec 10. doi: 10.1002/pds.5582 |
||||
| , Article | ||||
| , Denmark, Finland, Netherlands , Sweden, USA | ||||
| Abstract: https://onlinelibrary.wiley.com/doi/10.1002/pds.5582 | ||||
| Condition | Year | Language | Analysis type | |
| , Database Validity and methodology, Drug safety, Oncology | 2022 | English | , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Retrospective database analysis | |
| The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease | ||||
| Lars Holger Ehlers 1, Mark Lamotte 2, Sofia Monteiro 3, Susanne Sandgaard 4, Pia Holmgaard 4, Evan C Frary 4, Niels Ejskjaer 5 6 7 | ||||
| 1Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 2IQVIA Real World Solutions, Zaventem, Belgium. 3IQVIA Real World Solutions, London, UK. 4Boehringer Ingelheim Danmark A/S, København Ø, Hovedstaden, Denmark. 5Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. n.ejskjaer@rn.dk. 6Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk. 7Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk. | ||||
| Diabetes Therapy https://doi.org/10.1007/s13300-021-01040-y IQVIA HEOR Zaventem Brussels PMID: 33856655 PMCID: PMC8099952 DOI: 10.1007/s13300-021-01040-y |
||||
| , Denmark | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/33856655/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
| Comparison of electronic self-reported prescription medication use during pregnancy with the national prescription register in Denmark | ||||
| Maja Laursen 1, Christine E Hallgreen 2 3, Nancy Dreyer 4, Alison Bourke 5, Shahrul Mt-Isa 2 6, Stella Blackburn 5 | ||||
| 1The Danish Health Data Authority, Copenhagen, Denmark. 2School of Public Health, Imperial College London, London, UK. 3Copenhagen Center for Regulatory Science, Department of Pharmacy, SUND, University of Copenhagen, Copenhagen, Denmark. 4IQVIA Real-World and Analytic Solutions, Boston, Massachusetts. 5IQVIA Real-World and Analytic Solutions, London, UK. 6Biostatistics and Research Decision Sciences, MSD Research Laboratories, London, UK. | ||||
| Pharmacoepidemiol Drug Saf . 2020 Mar;29(3):328-336. doi: 10.1002/pds.4937. Epub 2019 Dec 6. |
||||
| , Article | ||||
| , Denmark, UK, USA | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/31811680/ | ||||
| Condition | Year | Language | Analysis type | |
| , Patient Registries & Real-World Study Methods, Pregnancy | 2020 | English | , Epidemiological study, Methodology, Patient questionnaire, Real World Data | |
| External Validation of the Core Obesity Model to Assess the Cost Effectiveness of Weight Management Interventions | ||||
| Sandra Lopes 1, Pierre Johansen 2, Mark Lamotte 3, Phil McEwan 4, Anamaria-Vera Olivieri 5, Volker Foos 4 | ||||
| 1Novo Nordisk A/S, Søborg, Denmark. snlb@novonordisk.com. 2Novo Nordisk A/S, Søborg, Denmark. 3IQVIA, Zaventem, Belgium. 4Health Economics and Outcomes Research Ltd, Cardiff, UK. 5IQVIA, Basel, Switzerland. | ||||
| Pharmacoeconomics 2020 https://doi.org/10.1007/s40273-020-00941-3 + Pharmacoeconomics. 2021 Jan;39(1):137-138. doi: 10.1007/s40273-020-00982-8. Epub 2020 Nov 30 |
||||
| , Article | ||||
| , Belgium, Denmark, Switzerland, UK | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/32656686/ | ||||
| Condition | Year | Language | Analysis type | |
| , Health economics, Obesity | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| The Cost-Effectiveness of Empagliflozin in Type 2 Diabetes in Denmark, Incorporating Cardiovascular Outcomes | ||||
| Ehlers LH, Lamotte M, Monteiro S, Sandgaard S, Holmgaard P, Frary EC, Staehr P, Ejskjaer N. | ||||
| IQVIA HEOR Zaventem Brussels | ||||
| ISPOR Europe 2020 Virtual conference Milano Nov 16-19 Abstract ID# 107114 |
||||
| , Poster | ||||
| , Denmark | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| A Survey Among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (Daratumumab) Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries | ||||
| Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi | ||||
| IQVIA, Courbevoie, France; Janssen EMEA, Medical Affairs, Italy; Janssen EMEA, Medical Affairs, UK | ||||
| Presented at ISPE’s 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2019), August 24–28, 2019 at the Pennsylvania Convention Center, Philadelphia, PA, USA. |
||||
| , Poster | ||||
| , Austria, Czech, Denmark, Finland, France, Germany, Hungary, Norway, Slovakia, Spain, Sweden, Switzerland | ||||
| Abstract: https://www.coodoc.com/pages/p1822-Daratumumab-ICPE-2019 | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology, Oncology | 2019 | English | , Public Health, Survey research | |
| Assessing the Outcomes for Orphan Status or Accelerated Assessment EMA Approved Medicines: A Comparison of Health Technology Assessment in Denmark, Finland, Norway and Sweden | ||||
| Falla, Edel; Pitcher, Ashley; Acs, Annabel; Heller, Vincent; Zhang, Rongrong | ||||
| IQVIA, Real-World Insights, London, LON, UK IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Solna, AB, Sweden IQVIA, Real-World Insights, Stockholm, Sweden | ||||
| ISPOR Europe 2019, November 5, 2019, Copenhagen, Denmark |
||||
| , Poster | ||||
| , Denmark, Finland, Nordic, Norway, Sweden | ||||
| Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(19)34089-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301519340896%3Fshowall%3Dtrue#%20 | ||||
| Condition | Year | Language | Analysis type | |
| , Comparative Effectiveness & Health Technology Assessment | 2019 | English | , Review | |
| Patient and caregiver indirect costs after acute cardiovascular events in Europe. | ||||
| Sidelnikov E1, Gerlier L2, Kutikova L1, Amarenco P3, Kotseva K4, Annemans L5 | ||||
| 1 Amgen (Europe) GmbH, Zug, Switzerland 2 IQVIA, Zaventem, Belgium 3 Paris-Diderot-Sorbonne University, Paris, France 4 National Heart & Lung Institute, Imperial College London, London, UK 5 Ghent University, Ghent, Belgium | ||||
| ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain |
||||
| , Oral presentation | ||||
| , Austria, Bulgaria, Croatia, Czech, Denmark, Finland, Germany, Greece, Italy, Norway, Romania, Slovakia, Slovenia | ||||
| Abstract: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/84816?pdfid=58963 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Health economics | 2018 | English | , Burden of illness, Cost of illness | |
| Feasibility Assessment for Conducting a Multi-Country Post-Marketing Safety Oncology Study Using Secondary Data Sources in Europe | ||||
| Wells KE, Jiang R, Tyczynski JE, Secrest M, Oliveria SA | ||||
| Wells KE: IQVIA; Jiang R: Abbvie; Tyczynski JE: Abbvie; Secrest M: IQVIA; Oliveria SA: IQVIA | ||||
| 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management |
||||
| , Abstract | ||||
| , Denmark, Finland, Germany, Norway, Sweden, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Database Validity and methodology, Oncology, Patient Registries & Real-World Study Methods | 2018 | English | , Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis, Review | |
| Different patterns of second?line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study | ||||
| Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW | ||||
| StatFinn & EPID Research, Espoo, Finland | ||||
| Endocrinol Diabetes Metab. |
||||
| , Article | ||||
| , Denmark, Finland, Nordic, Norway, Sweden | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354817/ | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Population Based Study, Retrospective database analysis | |
| Long-term patterns of adherence to medication therapy among patients with type 2 diabetes mellitus in Denmark: The importance of initiation | ||||
| Jensen ML1,2, Jørgensen ME1, Hansen EH2, Aagaard L3, Carstensen B1. | ||||
| 1 Steno Diabetes Center Copenhagen, Gentofte, Denmark. QuintilesIMS 2 Faculty of Health and Medical Sciences, Department of Pharmacy, Section for Social and Clinical Pharmacy, Universitetsparken 2, University of Copenhagen,Denmark. 3 Faculty of Health, University of Southern Denmark, Odense, Denmark. | ||||
| PLoS One. 2017; 12(6): e0179546. |
||||
| , Article | ||||
| , Denmark, Nordic | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493299/ | ||||
| Condition | Year | Language | Analysis type | |
| , Clinical practice, Diabetes | 2017 | English | , clinical setting: Secondary care, Compliance, Epidemiological study, Retrospective cohort analysis | |
| COMMONALITIES AND DIFFERENCES IN DATA COLLECTION ACROSS EUROPEAN SPONDYLOARTHRITIS REGISTRIES | ||||
| M. L. Hetland* 1, M. Østergaard1, J. Askling2, C. Gabay3, D. Nordstrom4, O. FitzGerald5, M. Hernández Miguel6, M. Santos7 , Z. Rotar8, H. Mann9, F. Iannone10, M. J. Nissen3, E. Hauge1, J. Gomez-Reino11, F. DÃaz-González12, M. Tomsic8, K. Pavelka9, F. O'Shea5, C. Sullivan5, M. van de Sande13, I. E. van der Horst-Bruinsma13, G. J. Macfarlane14, G. T. Jones14, B. Gudbjørnsson15, T. K. Kvien16 on behalf of EuroSpA Study Group | ||||
| 1DANBIO, Glostrup, Denmark, 2ARTIS, Stockholm, Sweden, 3SCQM, Geneva, Switzerland, 4ROB-FIN, Helsinki, Finland, 5ASRI, Dublin, Ireland, 6BIOBADASER, Barcelona, Spain, 7reuma.pt, Almada, Portugal, 8biorx.si, Ljubljana, Slovenia, 9ATTRA, Prague, Czech Republic, 10GISEA, Bari, Italy, 11BIOBADASER, Santiago, 12BIOBADASER, Santa Cruz de Tenerife, Spain, 13ARC, Amsterdam, Netherlands, 14BSRBR-AS, Aberdeen, United Kingdom, 15ICEBIO, Reykjavik, Iceland, 16NORDMARD, Oslo, Norway | ||||
| EULAR, Madrid, 2017 |
||||
| , Abstract | ||||
| , Czech, Denmark, Finland, Ireland, Italy, Norway, Slovenia, Spain, Sweden, Switzerland | ||||
| Abstract: http://ard.bmj.com/content/76/Suppl_2/656.3 | ||||
| Condition | Year | Language | Analysis type | |
| , Rheumatology | 2017 | English | , Epidemiological study | |
| Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. | ||||
| Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1. | ||||
| 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden. | ||||
| Clinical Epidemiology |
||||
| , Article | ||||
| , Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pmc/articles/PMC4887072/ | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2016 | English | , Literature Review | |
| An International Study of the Ability and Cost-Effectiveness of Advertising Methods to Facilitate Study Participant Self-Enrolment Into a Pilot Pharmacovigilance Study During Early Pregnancy. | ||||
| Richardson JL1, Stephens S1, Thomas SH1, Jamry-Dziurla A2, de Jong-van den Berg L3, Zetstra-van der Woude P3, Laursen M4, Hliva V5, Mt-Isa S6, Bourke A7, Dreyer NA8, Blackburn SC9. | ||||
| 1The UK Teratology Information ServiceNewcastle upon Tyne Hospitals NHS Foundation TrustNewcastle upon TyneUnited Kingdom; Institute of Cellular MedicineNewcastle UniversityNewcastle upon TyneUnited Kingdom. 2Department of Medical Genetics Poznan University of Medical Sciences Poznan Poland. 3Unit of PharmacoEpidemiology and PharmacoEconomics Department of Pharmacy University of Groningen Groningen Netherlands. 4Department of Data Delivery and Medicinal Product Statistics The Danish Health Data Authority Copenhagen Denmark. 5Quintiles Real-World and Late Phase Research St. Prex Switzerland. 6Imperial Clinical Trials Unit School of Public Health Imperial College London London United Kingdom. 7Real World Evidence Solutions IMS Health London United Kingdom. 8Quintiles Real-World & Late Phase Research Cambridge, MA United States. 9Quintiles Real-World and Late Phase Research Reading United Kingdom. | ||||
| , Article | ||||
| , Denmark, Netherlands, Poland, UK | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869218/pdf/publichealth_v2i1e13.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Womens Health | 2016 | English | , direct-to-patient research | |
| Use of Contraindicated Drugs in Pediatric Outpatients in the Nordic Countries | ||||
| Prami T, Långström D, Iso-Mustajärvi I, Sandler N | ||||
| EPID Research, Espoo, Finland | ||||
| Pharmacoepidemiology and Drug Safety (2016):25 (S3): pp. 3-679 |
||||
| , Abstract | ||||
| , Denmark, Finland, Norway, Sweden | ||||
| Abstract: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.4070 | ||||
| Condition | Year | Language | Analysis type | |
| , Pediatrics | 2016 | English | , Retrospective database analysis | |
| Direct-to-Patient Research: Piloting a New Approach to Understanding Drug Safety During Pregnancy | ||||
| Nancy A Dreyer1, MPH, PhD ;Stella CF Blackburn2, MBBS, MA, MSc ; Shahrul Mt-Isa3, BSc, PhD ; Jonathan L Richardson4,5, BBSc (Hons) ; Simon Thomas4,5, BSc, MD, FRCP ; Maja Laursen6, MSc, PhD ; • Priscilla Zetstra-van der Woude7, MSc ; Anna Jamry-Dziurla8, MSc ; Valerie Hliva9, PhD ; Alison Bourke10, BSc, MSc ; Lolkje de Jong-van den Berg7, PharmD, PhD | ||||
| 1Quintiles Real-World & Late Phase Research, Cambridge, MA, United States | ||||
| , Article | ||||
| , Denmark, Netherlands, Poland, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Pregnancy | 2015 | English | , direct-to-patient research, Internet or Interactive voice response system, Prospective study | |
| Direct-to-Patient Research: Piloting a New Approach to Understanding Drug Safety During Pregnancy. | ||||
| Dreyer NA1, Blackburn SC2, Mt-Isa S3, Richardson JL4, Thomas S4, Laursen M5, Zetstra-van der Woude P6, Jamry-Dziurla A7, Hliva V8, Bourke A9, de Jong-van den Berg L6. | ||||
| 1Quintiles Real-World & Late Phase Research Cambridge, MA United States. 2Quintiles Real-World & Late Phase Research Reading United Kingdom. 3Imperial College London United Kingdom. 4Institute of Cellular MedicineNewcastle UniversityNewcastle upon TyneUnited Kingdom; UK Teratology Information ServiceNewcastle HospitalsNHS Foundation TrustNewcastle upon TyneUnited Kingdom. 5Statens Serum Institut Copenhagen Denmark. 6University of Groningen Groningen Netherlands. 7Poznan University of Medical Sciences Poznan Poland. 8Quintiles Real-World & Late-Phase Research St. Prex Switzerland. 9IMS London United Kingdom. | ||||
| JMIR Public Health Surveill. 2015 Dec 22;1(2):e22. |
||||
| , Article | ||||
| , Denmark, Netherlands, Poland, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Womens Health | 2015 | English | , direct-to-patient research | |
| Combining electronic healtcare databases in Europe to allow for large-scale drug safety monitoring : the EU-ADR Project. | ||||
| Coloma PM, Schuemie MJ, trifiro G, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Corrao G, Pedersen L, Van Der Lei J, Sturkenboom M, EU-ADR Consortium. | ||||
| Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):1-11. doi: 10.1002/pds.2053. Epub 2010 Nov 8. |
||||
| , Article | ||||
| , Denmark, Italy, Netherlands, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21182150 | ||||
| Condition | Year | Language | Analysis type | |
| , Methodology | 2011 | English | ||
| EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. | ||||
| Trifiro G, Patadia V, Schuemie MJ, Coloma PM, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, giaquinto C, Scotti L, Avillach P, Sturkenboom MC, van der Lei J, Eu-Adr group. | ||||
| Stud Health Technol Inform. 2011;166:25-30. |
||||
| , Article | ||||
| , Denmark, Italy, Netherlands, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21685607 | ||||
| Condition | Year | Language | Analysis type | |
| , Methodology | 2011 | English | ||
| Daily costs of Prostaglandin analogues as monotherapy or in fixed combinations with Timolol, in Denmark, Finland, Germany and Sweden | ||||
| Bergstrom A1, Maurel F2, Le Pen C3, Lamure E2, Kent M4, Bardoulat I2,Berdeaux GH5,6 | ||||
| 1 Lund Hospital, Lund, Sweden 2 IMS France, Puteaux, France 3 Université Paris-Dauphine, Paris, France 4 Alcon Inc, Fort Worth, Texas, USA 5 Alcon France SA, Rueil-Malmaison, France 6Conservatoire National des Arts et Métiers, Paris, France | ||||
| Clin Ophthalmol. 2009;3:471-81 |
||||
| , Article | ||||
| , Denmark, Finland, Germany, Nordic, Sweden | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732058/?tool=pubmed | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2009 | English | , Economic evaluation | |
| Does pharmaceutical consumption improve healthcare status? | ||||
| Grandfils N1, Hauser S1, Amalric F1, Le Pen C2 | ||||
| 1IMS Health, Puteaux, France, 2Paris Dauphine University, Paris, France | ||||
| ISPOR 12th Annual European Congress, Paris, France, 24–27th October 2009 |
||||
| , Abstract, Poster | ||||
| , Denmark, France, Germany, Italy, Spain, Sweden, UK | ||||
| Abstract: http://www.ispor.org/congresses/paris1009/posters1.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Health policy | 2009 | English | , Economic evaluation | |